Rapid and risk-minimized development

ATRIVA focusses on the development of ATR-001, a MEK inhibitor already with clinical exposure in oncology and abandoned by the originator, as to the most favourable patent situation for the company. The development and patenting of a proprietary dosage form in conjunction with the already existing IP on usage of MEK inhibitors fighting influenza provides excellent USPs for ATRIVA’s ATR-001 drug candidate.